Clinical trial · Observational
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* To find out the gap between real-world clinical practice and guideline recommendations in initial management of DTC patients * To observe the characteristics of patients who achieved and did not achieve TSH target value after one year follow-up * To assess response to initial therapy in patients who undergo total or near-total thyroidectomy and RAI remnant ablation after one year follow-up (according to an modified dynamic risk stratification system) * To observe the recurrence status after one year follow-up
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- 2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
Primary outcomes (4)
- measure
- Proportion of patients who underwent total/near-total thyroidectomy
- timeFrame
- one year
- measure
- 2. Proportion of patients who were treated by 131I after undergoing total/near-total thyroidectomy
- timeFrame
- one year
- measure
- Proportion of patients who achieved serum TSH target value
- timeFrame
- one year
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients who are diagnosed as DTC (the diagnosis should base on pre-operative examinations and post-operative pathology report) 2. Patients who undergo the first-time thyroidectomy 3. Patients who are identified as intermediate-risk or high-risk of recurrence after thyroidectomy (according to the recurrence risk stratification of Chinese management guideline for patients with thyroid nodules and differentiated thyroid cancer published in 2012) 4. Patients who have Chinese nationality 5. Patients who have signed an informed consent form Exclusion Criteria: 1. History of thyroid surgery 2. Other malignant tumors 3. Severe organ damage such as heart failure of New York Heart Association classes III-IV, liverfailure, respiratory failure, renal failure, etc. 4. Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent 5. Legal incapacity or limited legal capacity 6. Unwilling to be followed up
References
Publications (1)
- DERIVEDLi C, Li S, Zhao Y, Zhang D, Fu Y, Zhou L, Li J, Li F, Du R, Liang N, Sun H. Prognostic Value of Hematological Inflammatory Indices (PLR, NLR, SII) in Medium and High-Risk Papillary Thyroid Carcinoma: A Multicenter Cohort Study. Clin Endocrinol (Oxf). 2026 Mar;104(3):255-269. doi: 10.1111/cen.70046. Epub 2025 Oct 16. PMID 41102848